Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.

The proportion of subjects with no significant nausea was significantly higher in the fosaprepitant group in the overall phase (83.1% versus 78.3%, P = 0.026), but between-group differences in the proportions of subjects with no nausea or no rescue medication use did not reach statistical significance (65.3% versus 61.6%, P = 0.156 and 83.9% versus 79.5%, P = 0.069, respectively).

also in 111,027 other papers